[Clinical use of heparin-heparinoid-mixtures].
D000074:Acenocoumarol / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000925:Anticoagulants / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D003374:Coumarins / Q000627:therapeutic use*; D004304:Dosage Forms; D004357:Drug Synergism; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use*; D006496:Heparinoids / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D011479:Protamines / Q000494:pharmacology; D013924:Thrombophlebitis / Q000188:drug therapy; D013927:Thrombosis / Q000188:drug therapy; D013997:Time Factors
D000925:Anticoagulants; D003374:Coumarins; D004304:Dosage Forms; D006496:Heparinoids; D011479:Protamines; D006493:Heparin; D000074:Acenocoumarol
Zur klinischen Anwendung von Heparin-Heparinoid-Gemischen.